Abstract: Embodiments of the present invention provide a secure edge device for contactless resource distribution and resource crediting from an automobile. In this way, the edge device may be affixed to or embedded within the side or the mirror of an automobile and be able to communicate with a third party device using near field communication. Upon authentication of a user, the edge device may communicate with the third party to transmit and present data about the resource distribution to the automobile display. The system allows for the user to select the resource distribution via the automobile display and provide a completion of resource distributions.

Abstract: Embodiments of the present invention provide a system for monitoring a cybersecurity mesh network comprising a distributed sensor grid and a plurality of devices for detection of one or more security incidents. In response to determining that one of the one or more security incidents has occurred, and in response to receiving the request from an identified device that requires the first level of authentication, transmitting to the identified device a request for authentication credentials that meet a second level of authentication, wherein the second level of authentication is more strict than the first level of authentication.

Abstract: An Automated Teller Machine (ATM) terminal receives a transaction request from a user. The ATM terminal triggers a camera to capture a first image of the authentication media item presented by the user, where the first image of the authentication media item is embedded with a first unique code. The ATM terminal compares the first image of the authentication media item with a second image of the authentication media item that is associated with the user, where the second image of the authentication media item is embedded with a second unique code for verifying the user. The ATM terminal determines whether the first unique code corresponds to the second unique code. The ATM terminal conducts the transaction request if it is determined that the first unique code corresponds to the second unique code.

Abstract: By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.

Abstract: By individually metering and dispensing specific volumes and/or weights of each component of a dosage, an amount of the components for each dose is secured with very high accuracy. A method for dosing a pharmaceutical product in a sealed container, such as, for example, a packet, sachet, blister pack, or other unit dose form. The dosage may include a first component that is a thickening agent and a second component that is an active ingredient. The thickening agent serves as a carrier that allows the active ingredient to dissolve in the mouth and be swallowed without the administration of water. The method includes providing the first component by measuring the volume or weighing the mass of the first component and measuring the volume or weighing the mass of the second component. Subsequent components may also be individually measured or weighed before being added to a package.

Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.

Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.

Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.

Abstract: The invention relates to the formulation and quality control of liquid drug suspensions. In particular, the invention relates to methods of formulating liquid suspensions comprising drug-containing resin particles. The invention also relates to methods of confirming the acceptability of drug-containing resin particles for use in formulating liquid drug suspensions. The invention further relates to methods of formulating liquid suspensions in which drug-containing resin particles, the liquid suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel dissolution method and methods of predicting in vivo bioequivalence based on in vitro dissolution methods.